Mechanisms of Skeletal Muscle/Organ Wasting

Speakers:
Imed Gallouzi, Phd – McGill University, Canada
The iNOS/NO pathway drives mitochondrial dysfunction to promote cancer-induced muscle wasting

Norbert Perrimon, PhD – Harvard Medical School, USA
Insights on cachexia from a Drosophila model of organ wasting

Daniel Marks
, MD, PhD – Oregon Health & Science University, USA

Bystander brain injury in cancer cachexia

Danna Breen
, PhD – Pfizer, USA
Growth differentiation factor 15 (GDF-15) is a key regulator of cancer cachexia

The speaker's disclosure of Conflict of Interest is available on the conference website.


Learning Objectives:
At the end of this presentation, the participant will be able to:
1 - Describe a proof of concept supporting the idea that iNOS could represent a novel therapeutic target to treat cancer-induced cachexia.
2 - Discuss the possible repurposing a clinically tested iNOS inhibitor to be used as anti-cachectic drug.
3 - Evaluate the power of modeling cachexia in a model organism.
4 - Summarize the conservation of signaling pathways involved in organ wasting.
5 - Identify the role of central nervous system inflammation in cancer cachexia.
6 - Describe potential therapeutic targets for anorexia and fatigue in cancer patients.
7 - Recognize, the role of GDF-15 in platinum-based chemotherapy-induced emesis, anorexia and weight loss, and survival.

Chairs:
Andrew Judge, PhD – University of Florida, USA
Paola Costelli, PhD – University of Torino, Italy
 

Please rate from low (1) to high (5).

Question Title

* 1. Your name and email (this information will not be shared with anyone)

Question Title

* 2. Please rate the quality of the session on a scale of 1 (strongly disagree) to 5 (strongly agree).

  1 - Strongly Disagree 2 - Disagree 3 - Neutral 4 - Agree 5 - Strongly Agree
Met the stated learning objectives
Enhanced my knowledge
Satisfied my expectations
Conveyed information that applied to my practice
Allocated at least 25% of the time for interaction
Was free from commercial bias

Question Title

* 3. If you perceived any sources of commercial bias, please describe:

(ranked the previous question a 1 or 2)

Question Title

* 4. What did you learn or how will this educational session impact your practice?

Question Title

* 5. Please indicate which CanMEDS roles you felt were addressed during this educational activity?

Question Title

* 6. Please rate the presenter, Dr. Imed Gallouzi :

  1 - Bad 2 - Not Bad 3 - Good 4 - Very Good 5 - Extremely Good
Knowledge
Presentation Skills
Topic Relevance

Question Title

* 7. Please rate the presenter, Dr. Norbert Perrimon:

  1 - Bad 2 - Not Bad 3 - Good 4 - Very Good 5 - Extremely Good
Knowledge
Presentation Skills
Topic Relevance

Question Title

* 8. Please rate the presenter, Dr. Daniel Marks:

  1 - Bad 2 - Not Bad 3 - Good 4 - Very Good 5 - Extremely Good
Knowledge
Presentation Skills
Topic Relevance

Question Title

* 9. Please rate the presenter, Dr. Danna Breen:

  1 - Bad 2 - Not Bad 3 - Good 4 - Very Good 5 - Extremely Good
Knowledge
Presentation Skills
Topic Relevance

Question Title

* 10. Please rate the overall session:

  1 - Bad 2 - Not Bad 3 - Good 4 - Very Good 5 - Extremely Good
Mechanisms of Skeletal Muscle/Organ Wasting

Question Title

* 11. Any additional comments?

T